Skip to NavigationSkip to content

Roche's Tecentriq/Cotellic combo therapy fails to impress in colorectal cancer

Published on 11/05/18 at 10:16am

Roche has been rocked by a Phase 3 weak showing from its combination Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal cancer (CRC), which failed to meet its primary endpoint in patient’s whose disease progressed or who proved intolerant to at least two systemic chemotherapy regimens.

The combo did not live up to expectations, failing to improve overall survival (OS) compared to regorafenib (Bayer’s Stivarga). Over 95% of the 363 participants enrolled in the trial have microsatellite stable (MSS) tumours, which, according to available data, have not proved clinically responsive to checkpoint inhibitors as monotherapy. This was reinforced in the results of the trial, where the Tecentriq-alone group did not see clinically-meaningful results.

The safety profile of the drug pair remained consistent with previous findings.  

“While these results are not what we hoped for, we remain committed to applying our deep experience to develop medicines that will improve outcomes for people living with gastrointestinal cancers,” said Dr Sandra Horning, Roche’s Chief Medical Officer and Head of Global Product Development. “In particular, we have a number of studies evaluating medicines in colorectal cancer that could play an important role in the treatment of people with this disease in the future.”

Matt Fellows


This kind of cancer is mainly affecting the stomach parts. Even I am also in research about different kind of cancers that are existing in the world. Recently I have gone through an article in blogs they stated that this cancer will affect the digestive system more. The food habits must be very healthy in order to avoid this kind of cancers.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches